Farxiga Approved to Reduce Risk for CKD Progression

MONDAY, May 3, 2021 -- Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday. The drug is the first to be approved to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news